<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118950</url>
  </required_header>
  <id_info>
    <org_study_id>ReMet</org_study_id>
    <nct_id>NCT00118950</nct_id>
  </id_info>
  <brief_title>Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet</brief_title>
  <official_title>Effect of Metformin Versus Repaglinide Treatment on Glycemic Control and Non-Glycaemic Cardiovascular Risk Factors in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <brief_summary>
    <textblock>
      Background: Metformin is the first drug of choice in obese patients with type-2 diabetes
      (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In
      non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim
      of this study was to evaluate the effect of metformin versus an insulin-secretagogue,
      repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in
      non-obese patients with T2DM.

      Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96
      non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only
      treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d).
      followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months
      with a one month wash-out between interventions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date>March 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HaemoglobinA1c</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Home-monitored 7-point plasma-glucose profiles</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body-weight</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist- and hip-circumference</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting and postprandial (after a standard test-meal) measures of plasma-glucose, insulin, c-peptide, free fatty acids, lipoproteins, triglycerides and other markers related to lipid-metabolism (e.g. apo-lipoproteins, lipoprotein particle size etc.).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers related to inflammation, endothelial dysfunction and fibrinolysis (e.g. hs-CRP, TNF-alpha, IL-6, ICAM, VCAM, E-selectin, vWF, PAI-1 and t-PA, adiponectin, ADMA, AGE-peptides).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria and 24-hour blood-pressure measurements.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation, markers of platelet activity and fibrinolytic markers fasting as well as before and after physical activity.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA for genotyping.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and safety variables (e.g. hypoglycaemia, haemoglobin, white blood cell count, cobalamine and folate).</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment>100</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Run-in period: Treatment: Diet-only. Duration: One month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Wash-out period: Treatment: Diet-only: Duration: One month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Metformin.</intervention_name>
    <description>Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Repaglinide.</intervention_name>
    <description>Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet-only.</intervention_name>
    <description>Diet-only treatment. Duration: One month.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type-2 diabetes, defined as:

          -  Age at onset of diabetes ≥ 40 years

          -  Fasting serum C-peptide ≥ 300 pmol/l or a non-fasting or glucagon-stimulated serum
             C-peptide ≥ 600 pmol/l

          -  No history of ketonuria or ketoacidosis.

          -  BMI ≤ 27 kg/m2.

          -  Fasting plasma-glucose ≥ 6.5 mmol/l after at least one month of diet-only treatment.

          -  HbA1c ≤ 9.5% at ongoing oral anti-hyperglycaemic agents. HbA1c ≥ 6.5% after minimum
             one month of diet-only treatment.

          -  Weight-loss of no more than 5.0 kg during the last 6 months prior to enrolment.

        Exclusion Criteria:

          -  Type-1 diabetes

          -  Insulin-treated type-2 diabetes

          -  Secondary diabetes, heart-failure

          -  Serum-creatinine above the upper limit

          -  Serum-ASAT elevated more than 3 fold above the upper limit

          -  Factor II-VII-X decreased below 0.7

          -  Ongoing coexisting illnesses with a life-shortening prognosis

          -  Mental retardation or reduced intellectual behaviour

          -  Pregnancy

          -  History of drug-abuse or HbA1c&gt;10.5% at two separate visits with at least one month
             interval during treatment-periods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan A Vaag, M. D., Chief Physician</last_name>
    <role>Study Chair</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soeren S Lund, M. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2005</study_first_submitted>
  <study_first_submitted_qc>July 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2005</study_first_posted>
  <last_update_submitted>December 5, 2008</last_update_submitted>
  <last_update_submitted_qc>December 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

